Press Releases
-
Apr 14, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Apr 6, 2020If approved, vosoritide would be the first medicine for the treatment of Achondroplasia in the US and EU
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company plans to submit marketing applications to the US...
Mar 9, 2020BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the
-
Feb 26, 2020- Full-year 2019 Total Revenues Increased 14% to $1.7 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2019 2018 % Change 2019 2018 % Change Total...
-
Feb 20, 2020No Advisory Committee Meeting Currently Planned to Review the Application
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for...
-
Feb 12, 2020- 9th Annual Leerink Partners Global Healthcare Conference on February 26 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February 26, 2020 at 10:00am ET in...
-
Feb 3, 2020Brian R. Mueller, Chief Accounting Officer and 17-year company veteran, named acting CFO
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman. Mr. Spiegelman will remain as an employee and...
-
Jan 29, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jan 13, 2020Health Authorities in the U.S. and U.K. Clear Path to Start of Clinical Trial, Patients Expected to be Dosed in Q1 2020 with Commercial Scale Material
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in treatments for the rare disease Phenylketonuria (PKU) and in gene therapy clinical research, announced today that both the U.S. Food and...
-
Jan 8, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual Healthcare CEOs Unscripted:...